Grace A McComsey1, Douglas Kitch, Paul E Sax, Camlin Tierney, Nasreen C Jahed, Kathleen Melbourne, Belinda Ha, Todd T Brown, Anthony Bloom, Neal Fedarko, Eric S Daar. 1. *Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, OH; †Harvard School of Public Health, Boston, MA; ‡Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; §Social & Scientific Systems, Inc., Silver Spring, MD; ‖Gilead Sciences, Foster City, CA; ¶GlaxoSmithKline, Research Triangle, NC; #Department of Medicine, Johns Hopkins University, Baltimore, MD; **Frontier Science and Technology Research Foundation, Amherst, NY; ††Department of Geriatric Medicine and Gerontology, Johns Hopkins University, Baltimore, MD; ‡‡Department of Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA.
Abstract
BACKGROUND: The association of inflammatory biomarkers with clinical events after antiretroviral therapy initiation is unclear. METHODS:A5202 randomized 1857 treatment-naive subjects toabacavir/lamivudine or tenofovir-DF/emtricitabine with efavirenz or atazanavir/ritonavir. Substudy A5224s measured inflammatory biomarkers on subjects with available plasma from baseline and week 24 or 96. An exploratory analysis of the association of high-sensitivity C-reactive protein, interleukin-6 (IL-6), soluble receptors of tumor necrosis factor α (sTNF)-RI, sTNF-RII, TNF-α, soluble vascular cellular adhesion molecules (sVCAM-1), and soluble intercellular adhesion molecules (sICAM-1) with times to AIDS and to non-AIDS events used Cox proportional hazards models. RESULTS: Analysis included 244 subjects; 85% men and 48% white non-Hispanic with median age 39 years, HIV-1 RNA of 4.6 log10 copies per milliliter, and CD4 of 240 cells per microliter. Overall, 13 AIDS events (9 opportunistic infections, 3 AIDS-cancers, and 1 recurrent bacterial pneumonia) and 18 non-AIDS events (6 diabetes, 4 cancers, 3 cardiovascular, and 5 pneumonias) occurred. Higher baseline IL-6, sTNF-RI, sTNF-RII, and sICAM-1 were significantly associated with increased risk of AIDS-defining events. Adjustment for baseline HIV-1 RNA did not change results, whereas adjusting for baseline CD4 count left only sTNF-RI and sICAM-1 significantly associated with increased risk. Time-updated values of IL-6, sTNFR-I and II, and sICAM-1 were also associated with an increased risk. For non-AIDS events, only higher baseline high-sensitivity C-reactive protein was significantly associated with increased risk, whereas higher IL-6 was marginally associated with higher risk. Analyses of time-updated biomarker values showed tumor necrosis factor α to be significantly associated with increased risk, even after adjustment for antiretroviral therapy, and CD4 count or HIV-1 RNA. CONCLUSIONS:Higher levels of several inflammatory biomarkers were independently associated with increased risk of AIDS and non-AIDS events.
RCT Entities:
BACKGROUND: The association of inflammatory biomarkers with clinical events after antiretroviral therapy initiation is unclear. METHODS: A5202 randomized 1857 treatment-naive subjects to abacavir/lamivudine or tenofovir-DF/emtricitabine with efavirenz or atazanavir/ritonavir. Substudy A5224s measured inflammatory biomarkers on subjects with available plasma from baseline and week 24 or 96. An exploratory analysis of the association of high-sensitivity C-reactive protein, interleukin-6 (IL-6), soluble receptors of tumor necrosis factor α (sTNF)-RI, sTNF-RII, TNF-α, soluble vascular cellular adhesion molecules (sVCAM-1), and soluble intercellular adhesion molecules (sICAM-1) with times to AIDS and to non-AIDS events used Cox proportional hazards models. RESULTS: Analysis included 244 subjects; 85% men and 48% white non-Hispanic with median age 39 years, HIV-1 RNA of 4.6 log10 copies per milliliter, and CD4 of 240 cells per microliter. Overall, 13 AIDS events (9 opportunistic infections, 3 AIDS-cancers, and 1 recurrent bacterial pneumonia) and 18 non-AIDS events (6 diabetes, 4 cancers, 3 cardiovascular, and 5 pneumonias) occurred. Higher baseline IL-6, sTNF-RI, sTNF-RII, and sICAM-1 were significantly associated with increased risk of AIDS-defining events. Adjustment for baseline HIV-1 RNA did not change results, whereas adjusting for baseline CD4 count left only sTNF-RI and sICAM-1 significantly associated with increased risk. Time-updated values of IL-6, sTNFR-I and II, and sICAM-1 were also associated with an increased risk. For non-AIDS events, only higher baseline high-sensitivity C-reactive protein was significantly associated with increased risk, whereas higher IL-6 was marginally associated with higher risk. Analyses of time-updated biomarker values showed tumor necrosis factor α to be significantly associated with increased risk, even after adjustment for antiretroviral therapy, and CD4 count or HIV-1 RNA. CONCLUSIONS: Higher levels of several inflammatory biomarkers were independently associated with increased risk of AIDS and non-AIDS events.
Authors: R Zangerle; S Steinhuber; M Sarcletti; M P Dierich; H Wachter; D Fuchs; J Möst Journal: Int Arch Allergy Immunol Date: 1998-07 Impact factor: 2.749
Authors: D V Havlir; F J Torriani; R D Schrier; J Y Huang; M M Lederman; K A Chervenak; W H Boom Journal: J Clin Microbiol Date: 2001-01 Impact factor: 5.948
Authors: E T Overton; D Kitch; C A Benson; P W Hunt; J H Stein; M Smurzynski; H J Ribaudo; P Tebas Journal: Clin Infect Dis Date: 2013-02-05 Impact factor: 9.079
Authors: Paul K Drain; Roland Kupka; Gernard I Msamanga; Willy Urassa; Ferdinand Mugusi; Wafaie W Fawzi Journal: AIDS Date: 2007-10-01 Impact factor: 4.177
Authors: F J Medrano; M Leal; D Arienti; C Rey; A Zagliani; Y Torres; A Sanchez-Quijano; E Lissen; M Clerici Journal: AIDS Res Hum Retroviruses Date: 1998-07-01 Impact factor: 2.205
Authors: Todd T Brown; Grace A McComsey; Martin S King; Roula B Qaqish; Barry M Bernstein; Barbara A da Silva Journal: J Acquir Immune Defic Syndr Date: 2009-08-15 Impact factor: 3.771
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Konstantia Angelidou; Peter W Hunt; Alan L Landay; Cara C Wilson; Benigno Rodriguez; Steven G Deeks; Ronald J Bosch; Michael M Lederman Journal: J Infect Dis Date: 2018-06-20 Impact factor: 5.226
Authors: Hongzheng Zhang; Sungjin Kim; Zhengjia Chen; Sreenivas Nannapaneni; Amy Y Chen; Charles E Moore; Gabriel Sica; Marina Mosunjac; Minh Ly T Nguyen; Gypsyamber D'Souza; Thomas E Carey; Lisa A Peterson; Jonathan B McHugh; Martin Graham; Christine M Komarck; Gregory T Wolf; Heather M Walline; Emily Bellile; James Riddell; Sara I Pai; David Sidransky; William H Westra; William N William; J Jack Lee; Adel K El-Naggar; Robert L Ferris; Raja Seethala; Jennifer R Grandis; Zhuo Georgia Chen; Nabil F Saba; Dong M Shin Journal: Head Neck Date: 2017-09-25 Impact factor: 3.147
Authors: James D Wilkinson; Paige L Williams; Wendy Yu; Steven D Colan; Armando Mendez; Justin P V Zachariah; Russell B Van Dyke; William T Shearer; Renee E Margossian; Steven E Lipshultz Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: S Dirajlal-Fargo; L Shan; A Sattar; E Bowman; J Gabriel; M Kulkarni; N Funderburg; R Nazzinda; V Musiime; G A McComsey Journal: HIV Med Date: 2019-10-23 Impact factor: 3.180
Authors: Jessica L Castilho; Bryan E Shepherd; John Koethe; Megan Turner; Sally Bebawy; James Logan; William B Rogers; Stephen Raffanti; Timothy R Sterling Journal: AIDS Date: 2016-03-27 Impact factor: 4.177